INT205991

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 13
Disease Relevance 1.81
Pain Relevance 0.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (SLC7A7) plasma membrane (SLC7A7) protein complex assembly (SLC7A7)
transmembrane transport (SLC7A7) cellular amino acid metabolic process (SLC7A7)
Anatomy Link Frequency
monocytes 3
macrophages 1
endothelial cells 1
fibroblasts 1
SLC7A7 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 48 72.48 Quite High
cytokine 15 62.04 Quite High
withdrawal 6 52.44 Quite High
member 8 6 10.08 Low Low
Cannabinoid receptor 12 5.00 Very Low Very Low Very Low
Angina 6 5.00 Very Low Very Low Very Low
Endocannabinoid 6 5.00 Very Low Very Low Very Low
cva 6 5.00 Very Low Very Low Very Low
antagonist 6 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pulmonary Alveolar Proteinosis 224 100.00 Very High Very High Very High
Disease 17 91.88 High High
Thalassemia 28 83.68 Quite High
Congenital Anomalies 13 79.68 Quite High
Toxicity 2 75.12 Quite High
Myelodysplastic Syndromes 19 71.68 Quite High
Aplastic Anemia 9 71.04 Quite High
Bone Disease 6 63.64 Quite High
Iron Overload 19 61.24 Quite High
Systemic Lupus Erythematosus 5 56.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
To assess if a different pattern of expression of SLC7A7/y+LAT1 and SLC7A6/y+LAT2 in LPI monocytes, macrophages and fibroblasts may justify the different transport phenotype of these cells, the expression of both genes was evaluated as number of mRNA molecules.
Negative_regulation (pattern) of SLC7A7 in monocytes
1) Confidence 0.41 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC2999609 Disease Relevance 0 Pain Relevance 0
Because of the genetic defect of SLC7A7/y+LAT1, the intracellular concentration of arginine is expected to be higher in LPI monocytes than in normal cells, although the scarce availability of the pathological samples prevents the quantification of arginine content in LPI monocytes/macrophages.
Negative_regulation (defect) of SLC7A7 in monocytes
2) Confidence 0.41 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC2999609 Disease Relevance 0.11 Pain Relevance 0.03
Because of the genetic defect of SLC7A7/y+LAT1, the intracellular concentration of arginine is expected to be higher in LPI monocytes than in normal cells, although the scarce availability of the pathological samples prevents the quantification of arginine content in LPI monocytes/macrophages.
Negative_regulation (higher) of LPI in monocytes
3) Confidence 0.36 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC2999609 Disease Relevance 0.12 Pain Relevance 0.03
Furthermore, preincubation of endothelial cells with 250 µM ouabain, which yielded strong membrane depolarization, reduced LPI (5 µM)-induced sustained depolarization from 20.1 ± 2.5–8.5 ± 1.5 mV (n= 9) (Figure 9B,C).
Negative_regulation (reduced) of LPI in endothelial cells
4) Confidence 0.16 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2931756 Disease Relevance 0.05 Pain Relevance 0.04
LPI elicits biphasic Ca2+ elevation, accompanied by diverse changes in membrane potential
Negative_regulation (elicits) of LPI
5) Confidence 0.15 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2931756 Disease Relevance 0 Pain Relevance 0
In line with these findings, the LPI-induced inward current (repetitive stimulation) was reduced upon addition of 2 mM Ni2+ into the bath by 50 ± 6% (Figure 7D).
Negative_regulation (reduced) of LPI
6) Confidence 0.15 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2931756 Disease Relevance 0 Pain Relevance 0.03
In line with these findings, LPI-induced Ni2+/La3+-insensitive depolarization was prevented by ouabain, an inhibitor of the Na/K-ATPase.
Negative_regulation (prevented) of LPI
7) Confidence 0.15 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2931756 Disease Relevance 0 Pain Relevance 0
Moreover, the Ca2+ entry blocker Ni2+ produced a gradual depolarization and diminished LPI-induced depolarization, thus, indicating that LPI-induced sustained depolarization requires Ca2+ entry.
Negative_regulation (diminished) of LPI
8) Confidence 0.15 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2931756 Disease Relevance 0 Pain Relevance 0
Under such conditions, LPI-induced sustained depolarization was reduced by 94 ± 3% compared with the respective control (Figure 8A).
Negative_regulation (reduced) of LPI
9) Confidence 0.15 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2931756 Disease Relevance 0 Pain Relevance 0
To assess if a different pattern of expression of SLC7A7/y+LAT1 and SLC7A6/y+LAT2 in LPI monocytes, macrophages and fibroblasts may justify the different transport phenotype of these cells, the expression of both genes was evaluated as number of mRNA molecules.
Negative_regulation (pattern) of SLC7A7 in fibroblasts
10) Confidence 0.14 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC2999609 Disease Relevance 0 Pain Relevance 0
To assess if a different pattern of expression of SLC7A7/y+LAT1 and SLC7A6/y+LAT2 in LPI monocytes, macrophages and fibroblasts may justify the different transport phenotype of these cells, the expression of both genes was evaluated as number of mRNA molecules.
Negative_regulation (pattern) of SLC7A7 in macrophages
11) Confidence 0.14 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC2999609 Disease Relevance 0 Pain Relevance 0
There is no evidence on the effectiveness of GM-CSF replacement for this condition: furthermore, it does not seem that GM-CSF signalling is impaired in PAP complicating LPI, thus suggesting a lack of rationale for substitutive treatment.
Negative_regulation (impaired) of LPI associated with pulmonary alveolar proteinosis
12) Confidence 0.07 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC1845139 Disease Relevance 1.03 Pain Relevance 0
Data from this study demonstrated that daily trough levels of deferasirox are sufficient to maintain suppression of LPI (Figure 5).64 After 4 weeks of treatment and throughout the remainder of the 1-year treatment period, peak LPI levels observed just before deferasirox dosing were significantly decreased compared with baseline and remained within normal values.
Negative_regulation (suppression) of LPI
13) Confidence 0.05 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2773754 Disease Relevance 0.49 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox